List view / Grid view
MSD/Merck reveals Keytruda® (pembrolizumab) significantly improved disease-free survival in adjuvant…
MSD/Merck reveals Keytruda® (pembrolizumab) significantly improved disease-free survival in adjuvant treatment of non-small cell lung cancer (NSCLC) patients.
Roughly 17.6 percent of patients treated with Imfinzi plus chemotherapy were alive…
Roughly 17.6 percent of patients treated with Imfinzi plus chemotherapy were alive at three years, versus 5.8 percent of chemotherapy patients.
Imfinzi (durvalumab) has been approved by the European Commission as…
Imfinzi (durvalumab) has been approved by the European Commission as a first-line treatment for extensive-stage small cell lung cancer, with chemotherapy.
